# DESCRIPTION

## BACKGROUND

- describe influenza history and current vaccine limitations

## SUMMARY

- introduce mosaic influenza antigenic polypeptides
- describe engineered HA polypeptides
- outline method for generating mosaic HA polypeptides
- align HA amino acid sequences
- identify epitopes and antigenic regions
- compile amino acid residues
- define set of amino acid sequence patterns
- select sequences for each epitope or antigenic region
- insert selected sequences into HA structural backbone
- describe alternative method for generating mosaic HA polypeptides
- generate consensus sequence from each set
- insert consensus sequences into HA structural backbone
- describe computational methods
- measure structural stability of mosaic HA polypeptide
- calculate folding energy
- select sequences based on sequence identity, geographical location, and isolation date
- weight patterns by frequency of occurrence
- select most frequently occurring sequence
- describe engineered mosaic NA polypeptides

## DEFINITIONS

- define singular and plural forms of terms
- define adjuvant
- define administer
- define affinity
- define animal
- define antibody
- describe antibody structure
- describe antibody classes
- define antigen
- describe antigen-antibody interaction
- define approximately
- define associated with
- define binding
- define carrier
- define characteristic portion
- define characteristic sequence element
- define codon-optimized
- define comparable
- define corresponding to
- define determine
- define engineered
- define epitope
- define host cell
- describe types of host cells
- define immune response
- describe types of immune responses
- define immunogen
- describe immunogenic compositions
- define in vitro
- define in vivo
- define influenza virus
- describe types of influenza viruses
- define influenza vaccine
- define isolated
- describe degrees of isolation
- define nucleic acid
- describe types of nucleic acids
- define recombinant
- define recombinant influenza vaccine
- define reference
- define specificity
- define subject
- define substantially
- define substantially similar
- define substantial identity
- define transformation
- define vaccination
- define vector and virus-like particle

## DETAILED DESCRIPTION OF CERTAIN EMBODIMENTS

- define scope of invention

### Engineering Mosaic Influenza Antigens

- introduce influenza viruses
- motivate need for broadly protective vaccine
- describe structural mapping of antigenic repertoires
- outline SMARt methodology
- describe hemagglutinin and antigenic drift
- motivate need for engineered HA polypeptides
- describe uses of engineered HA polypeptides
- outline techniques for obtaining and aligning influenza sequences
- describe Principal Components Analysis
- outline obtaining HA or NA protein sequences
- describe trimming and aligning sequences
- visualize principal components
- design modifications to engineered HAs or NAs
- describe assembly of mosaic pattern
- outline four SMARt workflows
- describe SMARt Random workflow
- describe SMARt Choice workflow
- describe SMARt Collapsed workflow
- describe SMARt Dominant workflow

### Exemplary Mosaic Sequence Patterns and Engineered HA Polypeptides

- define epitopes or antigenic regions
- describe receptor-binding site (RBS)
- determine RBS using crystal structures
- define RBS using reference HA polypeptide sequence
- describe mosaic sequence patterns for RBS
- provide examples of mosaic sequence patterns
- describe additional mosaic sequence patterns
- provide more examples of mosaic sequence patterns
- describe further mosaic sequence patterns
- provide additional examples of mosaic sequence patterns
- summarize mosaic sequence patterns and consensus sequences
- define mosaic sequence patterns
- provide exemplary mosaic amino acid sequence patterns
- describe full-length mosaic sequence patterns or consensus sequence templates
- explain generation of mosaic influenza HA or NA polypeptide
- discuss suitable structural backbone derivation
- provide exemplary backbone sequences
- describe engineered HA polypeptides with combinations of epitope sequences
- refine mosaic antigens by molecular modeling

### Nucleic Acid Construction and Expression

- construct expression vectors
- express nucleic acid molecules
- recover engineered HA polypeptides

### Conformation of Engineered HA or NA Polypeptides

- assess expression and conformation
- evaluate binding characteristics
- test in animal hosts

### Pharmaceutical Compositions

- provide pharmaceutical compositions including engineered HA or NA polypeptides
- formulate as immunogenic or vaccine compositions
- include inactivated virus, live attenuated influenza virus, virus-like particles, engineered HA or NA polypeptide, nucleic acid encoding engineered HA or
- NA polypeptide, DNA vector encoding engineered HA polypeptide, and/or expression system
- administer to prevent or treat influenza infections
- administer to subjects suffering from or susceptible to influenza infection
- test subjects for antibodies to engineered HA or NA polypeptides prior to administration
- select dose based on detection of antibodies
- memorialize selection of subject, engineered HA or NA polypeptide, and/or dose in written, printed, or electronic form
- administer prior to or after development of influenza infection symptoms
- treat influenza infections with engineered HA or NA polypeptides
- treat influenza infections with influenza VLPs
- treat influenza infections with vaccines
- provide vaccines comprising engineered HA polypeptides
- provide vaccines for immunogenic compositions
- administer to human subjects of various ages
- produce inactivated flu vaccines
- use reverse genetics methods to produce infectious reassortant influenza viruses
- use various plasmid methods for reverse genetics
- optimize nucleic acid sequences encoding engineered influenza HA polypeptides
- grow influenza virus in eggs or tissue culture for vaccine production

## EXAMPLES

- describe examples of engineered HA polypeptides

### Example 1. Design and Methodology for Construction of Hemagglutinin (HA) Polypeptides

- describe design and production of engineered HA polypeptides
- motivate mosaic antigens for cross-protection
- describe PCA to assess cross reactivity of influenza B HAs
- visualize protein relationships in sequence space
- describe modifications designed into engineered HAs
- describe assembly of mosaic pattern of B-cell epitopes
- describe structural mapping of antigenic repertoires
- describe structural modeling and selection of designs
- describe experimental validation of engineered HA proteins

### Example 2. Structural Mapping of Antigenic Repertoires (SMARt) Workflow

- describe SMARt approach for creating broadly protective HA-based vaccine
- identify and classify known B-cell epitopes for influenza A hemagglutinin
- describe creation of multiple sequence alignment
- identify epitopes for target protein of interest
- describe antigenic repertoires identification
- create cassette subsets of unique epitope sequence patterns
- create mosaic templates from cassettes
- evaluate alignment coverage of mosaic epitope templates
- optimize epitope sequence pattern swapping
- combine mosaic epitope template with target backbone templates
- describe structure refinement
- describe results of PCA analysis
- summarize results of SMARt approach

### CONCLUSIONS

- summarize SMARt approach for generating broadly protective vaccines

### Example 3. In Vivo Efficacy of Engineered Mosaic Influenza A HA and NA Polypeptides

- prepare VLPs containing engineered mosaic hemagglutinins
- immunize mice with VLPs expressing engineered mosaic HAs
- perform HAI and MN assays
- present results of immunogenicity studies

### Example 4. In Vivo Efficacy of Engineered Mosaic Influenza B HA Polypeptides

- immunize mice with rHAs and perform HAI assay

## EQUIVALENTS

- define claim interpretation rules
- specify inclusive language

